Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01959620 · ClinicalTrials.gov registry record · NA

Optimal Dose of Early Intervention to Prevent PTSD

A NA study of Posttraumatic Stress Disorder, sponsored by Emory University.

Completed
Registry status
NA
Development phase
95
Enrollment target
1
Study location

NCT01959620 is a NA study of Posttraumatic Stress Disorder that has completed, run by Emory University. The registered enrollment target is 95 participants, below the 111-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01959620, a NA study of Posttraumatic Stress Disorder, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
95 participants
Enrollment target
1
Study location

Study Summary

The overall aim of this study is to determine the optimal dose, 3-session exposure intervention versus 1-session exposure intervention compared to no treatment, for the delivery of exposure therapy in the immediate aftermath of trauma for preventing the development of posttraumatic stress disorder.

Interventions

  • BEHAVIORAL 1-Session Exposure Therapy
  • BEHAVIORAL 3-Session Exposure Therapy

Study Locations (1)

Georgia

  • Grady Memorial Hospital, Emergency Department - Atlanta

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2013-10
Est. Completion 2016-12
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT01959620

The ClinicalTrials.gov registry entry for NCT01959620 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (14% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Posttraumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which 1-Session Exposure Therapy is the first listed.

NCT01959620 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT01959620 about?

NCT01959620 is a clinical study titled "Optimal Dose of Early Intervention to Prevent PTSD". The overall aim of this study is to determine the optimal dose, 3-session exposure intervention versus 1-session exposure intervention compared to no treatment, for the delivery of exposure therapy in the immediate aftermath of trauma for preventing the development of posttraumatic stress disorder.

What is the current status of trial NCT01959620?

This trial is currently completed. It is a NA study. The enrollment target is 95 participants. The study started on 2013-10. Estimated completion is 2016-12.

What conditions does trial NCT01959620 study?

This clinical trial studies the following conditions: Posttraumatic Stress Disorder.

What interventions are being tested in trial NCT01959620?

The interventions under investigation include: 1-Session Exposure Therapy (BEHAVIORAL), 3-Session Exposure Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT01959620?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01959620 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Posttraumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.